Chimerigen

B7-H4 (human):Fc (mouse) (rec.)

CHF 460.00
In stock
CHI-HF-211B7H4-C100100 µgCHF 460.00
More Information
Product Details
Synonyms V-set Domain-containing T Cell Activation Inhibitor 1; VTCN1; B7h.5; Immune Costimulatory Protein B7-H4; T Cell Costimulatory Molecule B7x; Protein B7S1
Product Type Protein
Properties
Source/Host CHO cells
Sequence

The extracellular domain of human B7-H4 (aa 29-258) is fused to the N-terminus of the Fc region of mouse IgG2a.

Crossreactivity Human
Biological Activity

Measured by the ablility to inhibit anti-CD3-induced proliferation of stimulated human T cells.

MW ~80kDa (monomer)
Purity ≥95% (SDS-PAGE)
Endotoxin Content <1EU/mg protein (LAL test; Lonza).
Reconstitution Reconstitute with 100 µl sterile water.
Add 1X PBS to the desired protein concentration.
Formulation Lyophilized from 0.2μm-filtered solution in PBS.
Protein Negative Control

Fc (mouse) IgG2a Control (rec.)

Other Product Data

NCBI reference NP_078902.2: B7-H4 (human)

Declaration Manufactured by Chimerigen.
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Centrifuge lyophilized vial before opening and reconstitution.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

B7-H4 is a B7 family member that negatively regulates T cell immunity by inhibiting of T cell proliferation, cytokine production and cell cycle progression. In vitro, B7-H4 inhibits CD4+ and CD8+ T cell proliferation, cytokine production and generation of alloreactive cytotoxic T cells (CTLs). In vivo, blockade of endogenous B7-H4 by specific monoclonal antibody promotes T cell responses. B7-H4 ia an important negative regulator of innate immunity through growth inhibition of neutrophils. B7-H4 is expressed on some tumor cancer cells. The role of B7-H4 in tumor progression may be to transform precancerous cells and then protect them from immunosurveillance.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.